Mentioned in ?
References in periodicals archive ?
Stanford Researchers have now demonstrated in multiple clinical studies in patients that pharmacologic blockade of the GLP-1 receptor with Exendin (9-39) prevents hypoglycemia and improves symptoms.
Exendin (9-39) is a well-characterized compound that can be conveniently delivered as a targeted therapy, and encouraging clinical results have already been demonstrated by Dr.
Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans.
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma-suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 1992;267:7402-7405.
The Gila's venom contains the compound Exendin which is being turned into a new drug to fight Type 2 diabetes.
Exendin was isolated from the 18-inch Gila Monster's poisonous saliva by scientists studying the eating habits of animals.
Exendin 4 was studied and shown to decrease postprandial blood glucose and promote lower caloric intake and weight loss in patients with type 2 diabetes, a major achievement.
The last company announcement was in late December reporting that the US Patent & Trademark Office issued a Right of Appeal Notice of the patent called "Modified Exendins and Exendin Agonists" which was issued to Amylin Pharmaceuticals, Inc.
San Diego, USA, working on peptides and proteins related to amylin, leptin and exendin along with small molecule amylin antagonists, activators of mitochondrial uncoupling protein (UCPs) and anti-atherosclerotic compounds.
Exendin (Byetta) is the first representative of this new class of incretin mimetics, first approved in 2005 for the treatment of type 2 diabetes.
Exendin 4 -- Amylin Pharmaceuticals), Cone Snails (i.
The company has expanded its research and development pipeline within the filed of metabolic disorders by starting several new preclinical programs, including validation of exendin and GLP-1 for diabetes and obesity, the mono-di-tert-butylphenols for dyslipidemia, and several new drug targets for obesity.